Richard E. Showalter
9Patents
2h-index
21Co-inventors
47Inventor score
Filing activity: Sep 7, 1999 → Mar 29, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6316603A | Modifications of the VEGF receptor-2 protein and methods of use | Emerging Cross-Sectional Technologies | 5 | Expired |
| US9789170B2 | Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment | Emerging Cross-Sectional Technologies | 4 | Active |
| US10463721B2 | Engineered chimeric pegylated ADI and methods of use | Emerging Cross-Sectional Technologies | 1 | Active |
| US6784285B1 | Modifications of the VEGF Receptor-2 Protein and methods of use | Emerging Cross-Sectional Technologies | 0 | Expired |
| US11235037B2 | Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment | Emerging Cross-Sectional Technologies | 0 | Active |
| US6849721B2 | Modifications of the VEGF receptor-2 protein and methods of use | Emerging Cross-Sectional Technologies | 0 | Expired |
| US6794146B2 | Modifications of the VEGF receptor-2 protein and methods of use | Emerging Cross-Sectional Technologies | 0 | Expired |
| US6753416B2 | Modifications of the VEGF receptor-2 protein and methods of use | Emerging Cross-Sectional Technologies | 0 | Expired |
| US12344645B2 | Protein conjugates | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.